Latest from BioRegenx
July 26, 2022
BioRegenx Announces COVID-19 and Bacterial Sepsis Study Using Microvascular Health Solutions’ Testing Device GlycoCheck
BioRegenx subsidiary Microvascular Health Solutions (MVHS) announces that a new peer-reviewed study using GlycoCheck, exclusively distributed worldwide by MVHS, has been published. The study, published in Angiogenesis, is titled Microvascular and proteomic signatures overlap in COVID-19 and bacterial sepsis: the MICROCODE study. The study was conducted at the University Hospital Münster in Germany. One of the authors of the study was Hans Vink, PhD, Chief Science Officer of Microvascular Health Solutions.
July 19, 2022
BioRegenx Announces Investor Update
CEO, William Resides announces that as of July 1st, 2022, BioRegenx has moved from due diligence to a binding letter of intent to merge with a public company. These steps also include drafting the definitive agreement for the final merger.
Latest from Subsidiaries
August 2, 2022
Oncological Study of Endothelial Glycocalyx Integrity Using Microvascular Health Solutions’ Testing Device GlycoCheck
Microvascular Health Solutions (MVHS), a BioRegenx subsidiary, announces that a new peer-reviewed study using GlycoCheck, a medical testing device exclusively distributed worldwide by MVHS, has been published. The study, published by the International Journal of Cardiology, is titled Endothelial glycocalyx integrity in oncological patients. The study was conducted at the National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece, and led by Prof. Ignatios Ikonomidis.
December 26, 2020
NuLife Sciences Introduces PEMF Therapy Device, Sedona Face PEMF Thearapy
The benefits of PEMF (Pulsed Electro-Magnetic Field) therapy is no secret among wellness experts with a four-year study conducted by NASA to understand its benefits and effects on human wellbeing. NuLife Sciences introduces a portable and affordable PEMF therapy device called the Sedona Face.